Eli Lilly stock gets bump after positive results for its mid-stage diabetes drug trial

Markets Insider
  • On Thursday, pharma giant Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug. The company’s stock rose 3% on the news.
  • The drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes.
  • The late-stage trial for this drug is expected to be completed in 2021.
  • This drug has to potential to boost Lilly’s growing portfolio of drugs extending across the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health and musculoskeletal fields.

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.